BioSpace News Archive

March 24, 2021 Meeting was adjourned to provide additional time for stockholders to vote.

BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“ Bioasis ” or the “ Company ”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need

Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021.

LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of its initial public offering of 6,700,000 common shares at a public offering price of $15.00 per share.

Evofem Biosciences, Inc. announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share.

Angion Biomedica Corp. announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS.

Newly updated CPR and first aid training courses have been launched by ProMedify. They work with both health professionals and non-healthcare workers to provide valuable training that can be immediately applied in real-life situations.

The global dental preventive supplies market is expected to be uplifted by rising preference towards preventive healthcare.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021

Based on the model established at Blumberg Institute’s highly successful Pennsylvania Biotechnology Center (PABC), B.Labs will further accelerate scientific development in the booming University City, Philadelphia’s Life Science ecosystem